Abstract
Lipid management is the first line of treatment for decreasing the incidence of cardiovascular events in patients with coronary heart disease (CHD). This work analyses the differences in LDL-C and apoB for lipid management evaluation and explores the feasibility of skin cholesterol as a non-invasive marker. A prospective study of 121 patients with acute coronary syndrome (ACS) treated with rosuvastatin (10 mg/day) for 12 weeks was conducted. Results showed that LDL-C attainment rates were lower than apoB attainment rates, particularly in patients with low initial LDL-C. Skin cholesterol reduction significantly correlated with reductions in LDL-C (r=0.501, P < 0.001) and apoB (r=0.538, P < 0.001). The findings suggest that non-invasive skin cholesterol measurements have the potential to be used independently for lipid management evaluation.
Introduction
Effective lipid management is the cornerstone of preventing secondary cardiovascular events in patients with coronary heart disease (CHD). While low-density lipoprotein cholesterol (LDL-C) is the standard clinical marker, it has limitations—specifically, the commonly used Friedewald equation can be inaccurate in patients with high triglycerides or diabetes. Apolipoprotein B (apoB) is often a more accurate predictor of risk, but like LDL-C, it requires invasive blood draws and laboratory analysis.
This study addresses the need for a non-invasive, rapid, and reliable method to monitor lipid-lowering progress. The authors explore whether "skin cholesterol"—which accumulates in the skin in proportion to systemic atherosclerotic risk—can track the efficacy of statin therapy as effectively as traditional blood markers.
Methods and Study Design
The researchers conducted a prospective study of 121 patients diagnosed with acute coronary syndrome (ACS) at the First Affiliated Hospital of the USTC. Patients were treated with 10 mg/day of rosuvastatin and monitored for 12 weeks. The cohort was divided into two groups based on comorbidities:
- Group I (n=53): Patients with comorbid hyperlipidemia and/or diabetes mellitus.
- Group II (n=68): Patients without these comorbidities.
The core innovation is a non-invasive skin cholesterol detection system utilizing fluorescence spectroscopy. The hypothenar area of the palm was selected for testing due to its stable readings and low melanocyte count. A specific reagent binds to skin cholesterol, which then fluoresces under excitation light. The resulting spectrum is measured and compared to background signals to quantify cholesterol levels.
Key Insights and Results
- Correlation with Serum Markers: Skin cholesterol reduction showed a moderate but statistically significant correlation with both LDL-C ($r=0.501$) and apoB ($r=0.538$). This suggests skin cholesterol is a dynamic reservoir that mirrors systemic lipid changes rather than a static marker of past damage.
- ApoB as a Critical Metric: In patients starting with low LDL-C, apoB levels provided more informative data on lipid management. In Group I, 30 patients met apoB goals, but only 20 met LDL-C goals ($P < 0.05$), highlighting a potential "blind spot" in traditional monitoring.
- Temporal Tracking: Skin cholesterol reduction continued across all measured time points (weeks 2 through 12), demonstrating the test's ability to track long-term treatment efficacy non-invasively.
- Risk in Comorbid Patients: Patients in Group I (diabetes/hyperlipidemia) suffered ACS events at a significantly younger mean age (56.4 vs. 62.3 years), reinforcing the need for aggressive monitoring in high-risk groups.
Discussion and Conclusion
While this single-center study has limitations—including a relatively small sample size and a 12-week follow-up—it demonstrates the feasibility of skin cholesterol as a proxy for serum lipid trends. Factors such as age and skin tanning may influence baseline readings, but the study normalized for these by focusing on the reduction in levels during treatment.
Future work should involve larger, multi-center trials to validate these findings. The development of portable, handheld skin cholesterol testers could eventually allow for rapid primary care screening or home monitoring, similar to glucose meters for diabetics.
Summary updated